Skip to main content
OpenTrials
Completed

NCT Number: NCT03011177

Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 Diabetes Mellitus patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type2 Diabetes Mellitus

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Asan Medical Center

Seoul, South Korea

About this study

A randomized, open label, parallel-group, non-inferiority, active-controlled, phase IV study

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are 19 years or older on screening
  • Patients with type 2 diabetes mellitus
  • Patients with 7.0% ≤ HbA1c ≤ 11.0% at the screening visit
  • Patients with Fasting Plasma Glucose <15mmol/L(270mg/dL) on screening

Exclusion criteria

-

Treatment and study plan

teneligliptin

Drug

teneligliptin 20mg qd

Linagliptin

Drug

linagliptin 5mg qd

Primary outcomes

  1. HbA1c

    Time frame: 12week

Sponsors and collaborators

Lead sponsor

Handok Inc.

Industry

Registry information

Official study title

A Randomized, Open Label, Parallel-group, Non-inferiority, Active-controlled, Phase Ⅳ Study to Evaluate the Efficacy and Safety of Teneligliptin Versus Linagliptin in Type 2 Diabetes Mellitus Patients

Acronym: TELIUS

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jan 5, 2017
Registry last updated
Feb 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.